Ethylestrenol - Generic Drug Details

What are the generic sources for ethylestrenol and what is the scope of freedom to operate?

Ethylestrenol is the generic ingredient in one branded drug marketed by Organon Usa Inc and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for ethylestrenol

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	12
DailyMed Link:	ethylestrenol at DailyMed

Medical Subject Heading (MeSH) Categories for ethylestrenol

Anabolic Agents

Anatomical Therapeutic Chemical (ATC) Classes for ethylestrenol

A14AB	Estren derivatives
A14A	ANABOLIC STEROIDS
A14	ANABOLIC AGENTS FOR SYSTEMIC USE
A	Alimentary tract and metabolism

US Patents and Regulatory Information for ethylestrenol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Usa Inc	MAXIBOLIN	ethylestrenol	TABLET;ORAL	014005-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Organon Usa Inc	MAXIBOLIN	ethylestrenol	ELIXIR;ORAL	014006-002	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for Ethylestrenol

Last updated: February 14, 2026

Overview

Ethylestrenol is a synthetic anabolic steroid historically used for muscle growth, anemia treatment, and as a performance-enhancing agent. Due to its classification as a controlled substance in many jurisdictions and the shift toward safer alternatives, its current clinical and commercial use declines sharply. Major markets for anabolic steroids, including the U.S., EU, and Asia, have tightened regulations, constraining legal access and lowering authorized sales.

Regulatory Environment

• The International Olympic Committee and World Anti-Doping Agency list ethylestrenol as a banned substance.
• The U.S. Drug Enforcement Administration (DEA) classifies ethylestrenol under Schedule III, restricting prescription distribution.
• European Medicines Agency (EMA) ceased approval for most anabolic steroids, including ethylestrenol, due to safety concerns.
• These regulatory actions limit legal pathways for pharmaceutical distribution and reduce market size substantially.

Market Size and Trends

• Historically, ethylestrenol's global market was modest, driven mainly by prescription in certain countries and its popularity among athletes and bodybuilders.
• The decline is reflected in sales data, with estimates indicating that prescription-based sales in the U.S. and Europe have reduced by over 75% over the last decade.
• The underground market for performance enhancement sustains some demand but remains unpredictable and inaccessible to legitimate pharmaceutical firms.

Commercial and Scientific Developments

• No recent approvals for new indications or formulations.
• Safety concerns, including Hepatotoxicity, hypertension, and androgenic effects, have led to decreased research interest.
• Alternatives such as nandrolone, oxandrolone, and other newer anabolic steroids have taken dominance due to better safety profiles and legal accessibility.

Financial Trajectory

Year	Estimated Global Sales (USD millions)	Notes
2012	10	Mostly prescription sales in certain countries
2017	2	Decline driven by regulatory bans
2022	<1	Nearly phased out from legitimate markets

• The projected trend suggests continuous decline, with negligible market projections beyond 2025.
• R&D investments are minimal, focused mainly on forensic detection and control, not on development or commercialization.
• Underground markets obscure actual demand figures but are estimated to sustain a niche, highly unregulated demand, especially in the context of doping.

Future Considerations

• No current pipeline development or approved new formulations.
• Regulatory pressure and safety concerns will continue to constrict legitimate markets.
• Investment or partnership opportunities are limited to forensic and anti-doping applications.

Key Takeaways

• Ethylestrenol's legal market has contracted significantly due to regulatory bans and safety issues.
• Sales are expected to diminish further, with negligible prospects for new commercial development.
• The underground doping market sustains some demand but remains inaccessible to official pharmaceutical channels.
• Future trends favor safer, more effective anabolic steroids with fewer regulatory constraints.
• Industry focus has shifted away from ethylestrenol toward emerging therapies and research compounds.

FAQs

1. Is ethylestrenol still prescribed in any countries?
   Very few countries prescribe ethylestrenol; most have banned it due to safety concerns and regulatory changes.

2. What are the primary safety concerns associated with ethylestrenol?
   Liver toxicity, hypertension, androgenic side effects, and potential cardiovascular risks.

3. How has regulation impacted the global market for ethylestrenol?
   Regulations have drastically cut legal availability, reducing sales and research interest.

4. Are there ongoing research activities involving ethylestrenol?
   No substantial clinical research or development projects are known; focus has shifted to other compounds.

5. Could illicit markets sustain demand for ethylestrenol?
   Yes, particularly within doping communities, but this demand is unregulated and unpredictable.

References

[1] U.S. Drug Enforcement Administration (DEA) Schedule III listing.
[2] World Anti-Doping Agency banned substances list.
[3] Market research reports on anabolic steroid sales trends.